Skip to main content
SpringerLink
Log in

Nasale Glukokortikoide bei schwerer allergischer Rhinitis

Die Dokumentation ist entscheidend

  • AeDA/DGAKI informieren
  • Published:
Allergo Journal Aims and scope Submit manuscript

Nicht verschreibungspflichtige Nasensprays mit den Wirkstoffen Beclomethason, Fluticason und Mometason können ab sofort wieder „zur Behandlung bei persistierender allergischer Rhinitis mit schwerwiegender Symptomatik“ auf einem Kassenrezept verordnet werden. Dabei gilt es, gut zu dokumentieren, dass diese tatsächlich vorliegt. Der Ärzteverband Deutscher Allergologen hat hierfür einen Dokumentationsbogen entworfen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(Suppl 86):8–160)

    Article  Google Scholar 

  2. Meltzer EO. Allergic Rhinitis: Burden of Illness, Quality of Life, Comorbidities, and Control. Immunol Allergy Clin North Am 2016;36:235–48

    Article  Google Scholar 

  3. Fachinformation Dymista® (Stand März 2018)

  4. Carr W, Bernstein J, Lieberman P, Meltzer E, Bachert C, Price D, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 2012;129:1282–9

    Article  CAS  Google Scholar 

  5. Hampel FC, Ratner PH, Van Bavel J, Amar NJ, Daftary P, Wheeler W, et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol 2010;105:168–73

    Article  CAS  Google Scholar 

  6. Meltzer EO, Ratner P, Bachert C, Carr W, Berger W, Canonica GW, et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol 2013;161:369–77

    Article  CAS  Google Scholar 

  7. Berger WE, Shah S, Lieberman P, Hadley J, Price D, Munzel U, et al. Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis. J Allergy Clin Immunol Pract 2014;2:179–85

    Article  Google Scholar 

  8. Bousquet J, Meltzer EO, Couroux P, Koltun A, Kopietz F, Munzel U et al. Onset of Action of the Fixed Combination Intranasal Azelastine-Fluticasone Propionate in an Allergen Exposure Chamber. J Allergy Clin Immunol Pract 2018;6:1726–32.e6

    Article  Google Scholar 

  9. Klimek L, Bachert C, Stjärne P, Dollner R, Larsen P, Haahr P, et al. MP-AzeFlu provides rapid and effective allergic rhinitis control in real life: A pan-European study. Allergy Asthma Proc 2016;37:376–86

    Article  Google Scholar 

  10. Weißbuch Allergie in Deutschland, 4. Auflage, Springer Medizin 2018, Hrsg. DAL, AeDA, GPA, DGAKI

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Ludger Klimek

Authors
  1. Ludger Klimek
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Klimek, L. Die Dokumentation ist entscheidend. Allergo J 28, 92–93 (2019). https://doi.org/10.1007/s15007-019-1961-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15007-019-1961-3

Search

Navigation